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Abstract 
The alternative pathway of complement is implicated in the pathogenesis of several renal 
diseases, such as atypical hemolytic uremic syndrome, dense deposit disease and other forms 
of C3 glomerulopathy. The underlying complement defects include genetic and/or acquired 
factors, the latter in the form of autoantibodies. Because the autoimmune forms require a 
specific treatment, in part different from that of the genetic forms, it is important to detect the 
autoantibodies as soon as possible and understand their characteristics. In this overview, we 
summarize the types of anti-complement autoantibodies detected in such diseases, i.e. 
autoantibodies to factor H, factor I, C3b, factor B and those against the C3 convertases (C3 
nephritic factor and C4 nephritic factor). We draw attention to newly described autoantibodies 
and their characteristics, and highlight similarities and differences in the autoimmune forms of 
these diseases. 
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1. Introduction 
The complement system is one of the most powerful effector systems of innate immunity, 
providing protection against infections, participating in the clearance of immune complexes 
and cellular debris and influencing the adaptive immune response [1]. While it can effectively 
destroy microorganisms, a strict regulation ensures that complement does not harm host cells 
and tissues. Imbalance between complement activation and inhibition can lead to various 
diseases [2]. Genetic defects in complement components may manifest as complement 
deficiency or as altered function. In addition, acquired complement abnormalities due to 
autoantibodies against specific components are associated with several diseases, including 
kidney diseases such as C3 glomerulopathy, membranoproliferative glomerulonephritis 
(MPGN)1 and atypical hemolytic uremic syndrome (aHUS). 
 
1.1. Complement activation and inhibition 
Complement can be activated via three major pathways, the alternative, the classical and the 
lectin pathways [1] (Fig. 1). The alternative pathway is continuously and spontaneously 
activated by the hydrolysis of the tioester bond in the central component C3. The resulting 
C3(H2O) (also termed iC3) has „C3b-like” properties by acquiring the ability to bind to 
complement receptor type 1 (CR1, CD35), as well as to factor B. Factor D cleaves the 
C3(H2O)-bound factor B, which leads to the formation of the initial C3(H2O)Bb C3 
convertase enzyme of the alternative pathway that cleaves C3 into C3a and C3b. C3b forms 
additional convertases (C3bBb) which generate more C3b. The classical pathway is activated 
by target-bound immunoglobulins or pentraxins, which bind C1q and initiate the cascade. The 
lectin pathway is activated by target-bound mannan-binding lectin or ficolins. Activation of 
both the classical and the lectin pathways result in the generation of the classical/lectin 
pathway C3 convertase enzyme (C4bC2b), which cleaves C3 into C3a and C3b. Because C3b 
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feeds into the alternative pathway, the latter also represents a powerful „amplification loop” 
of the classical/lectin pathways. Thus, the three pathways lead to the generation of C3 
convertases and converge in the cleavage of the central complement component C3 into C3a 
and C3b, which is a critical step in complement activation and generation of opsonic 
molecules. 
The C3 convertases, when binding an additional C3b molecule, form the C5 
convertases (C3bBbC3b for the alternative pathway, and C4bC2bC3b for the classical/lectin 
pathway), which cleave C5 into C5a and C5b and thus initiate activation of the terminal 
pathway. The terminal pathway incorporates components C6 to C9, thus leading to the 
formation of terminal complement complexes (TCC or C5b-9), also called membrane attack 
complexes at cell surfaces and SC5b-9 when in solution bound to S protein (Fig. 1). 
Because of the central role of C3 and the C3 convertases in complement activation, it 
is not surprising that there is an array of regulatory molecules acting on C3 or the convertases. 
The spontaneous decay of C3 convertases can be accelerated by the membrane-bound 
proteins CR1 and decay accelerating factor (DAF, CD55), and the soluble regulators factor H 
(for the alternative pathway C3 convertase) and C4b-binding protein (for the classical/lectin 
pathway convertase). The only positive regulator is the plasma protein properdin, which 
extends the half-life of the C3bBb convertase. In addition, the complement regulator factor I 
is a serine protease that specifically cleaves and thus inactivates the C3b and C4b molecules 
in the presence of a cofactor. For C3b inactivation, factor I requires factor H, CR1 or 
membrane cofactor protein (MCP, CD46) as a cofactor. C4b inactivation by factor I proceeds 
in the presence of C4b-binding protein, MCP or CR1.  
Maintaining the delicate balance between complement activation and inhibiton is 
important under physiological conditions. Misdirected or exaggerated complement activation 
(e.g., due to overactivation or defective regulation) may cause various diseases [2,3]. In this 
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context, genetic alterations and/or autoantibodies to complement components are implicated 
in a growing number of diseases [4]. In the present review, we focus on the role of anti-
complement autoantibodies in the kidney diseases C3 glomerulopathies, particularly dense 
deposit disease (DDD), and aHUS. The common underlying pathomechanism of these renal 
diseases involves the complement system, and because often similar mutations or 
autoantibodies are detected in many patients, it was suggested that there is a disease spectrum 
of related disorders and the underlying defects manifest as different disease entities [5,6]. 
Here, we summarize the biological features and clinical characteristics of anti-complement 
autoantibodies and discuss similarities and differences in the autoimmune forms of C3 
glomerulopathies and aHUS. 
 
2. Autoantibodies in C3 glomerulopathy 
C3 glomerulopathy is characterized predominantly by C3 deposition in the glomeruli, usually 
in the absence of IgG, and complement activation due to dysregulation of the alternative 
pathway [7,8]. Several disease entities fall under the umbrella of C3 glomerulopathy, such as 
DDD (also termed MPGN II), CFHR5 nephropathy and C3 glomerulonephritis [8]. 
While anti-C1q antibodies have been described in patients with glomeulonephritis [9-
11], most known anti-complement autoantibodies in patients with C3 glomerulopathy target 
the C3 convertases (C3 and C4 nephritic factors, anti-factor B, anti-C3b) or factor H (anti-
factor H), a regulator of the alternative pathway C3 convertase. 
 
2.1. C3 nephritic factor 
The most common anti-complement autoantibodies reported in patients with C3 
glomerulopathy target the alternative pathway C3 convertase C3bBb. Regarding their epitope 
specificity, isotype and effect on the convertase, these C3 nephritic factors (C3Nefs) form a 
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heterogeneous group of autoantibodies with the common feature of preventing the 
dissociation of Bb from the convertase and thus prolonging the half-life of the convertase. 
C3Nefs are IgG or IgM antibodies that bind to the C3bBb convertase [12,13]. Most 
C3Nefs recognize a neoepitope on the C3bBb complex, but some of them are able to bind 
C3b or Bb alone [14]. Some C3Nefs require the presence of properdin, others are properdin-
independent [15,16]. All C3Nefs prevent the natural intrinsic decay of C3bBb [14,17], but the 
stabilized convertases are variously resistant against extrinsic decay mediated by factor H, 
CR1 or DAF [18-22]. Stabilization of the C3bBb convertase by C3Nef results in higher and 
prolonged activity, C3 and C5 consumption and activation of the terminal pathway [16,17]. 
However, certain C3Nefs were reported to inhibit C5 cleavage [23]. This functional 
heterogeneity is clearly mirrored in the studies and case reports. C3Nef has been detected in 
~50% in the cases of MPGN I and MPGN III, and in up to 80% of MPGN II/DDD patients 
[10,24,25]. Despite the strong association of C3Nef with MPGN, there is uncertainty 
regarding the nephritogenic role of C3Nef. Some studies support the correlation between 
C3Nef and disease course or complement status, while others found no evidence in this regard 
[26]. Furthermore, C3Nef is not exclusively associated with MPGN, its presence has been 
reported in patients with C3 glomerulonephritis without MPGN, partial lipodystrophy, 
poststreptococcal glomerulonephritis, systemic lupus erythematosus (SLE), meningococcal 
meningitis and also in healthy individuals [27-32].  
Consensus for the detection and characterization of C3Nefs is also lacking. The few 
laboratories routinely measuring C3Nef use different methods, predominantly hemolytic 
assays, and occassionally ELISA and surface plasmon resonance assay that detect various 
groups of C3Nefs [22,33-37]. Results of the various measurements can also be influenced by 
the presence of C4 nephritic factor (C4Nef), anti-C1q autoantibodies or mutations in factor H 
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or factor I [10,38-40]. Recent data suggest that a combination of different assays are likely to 
identify most C3Nefs, including occult cases [11,22,37]. 
The heterogeneity of C3Nefs in appearance and function and the difficulties in their 
detection and characterization led to some confusion in the literature, and leaves open the 
question, whether C3Nef is the primary cause of the disease or it emerges secondarily as a 
consequence of the prolonged existence of the convertase neoepitopes. DDD patients with 
C3Nef often present with hypocomplementemia [25], and C3- and/or C5 activation fragments 
can be observed in the glomerular deposits [41]. Thus, the presence of C3Nef can alter the 
disease course by promoting and adding to the enhanced complement activation. Further 
studies and characterization of individual C3Nefs could help understanding its role in disease 
pathogenesis in more detail. 
 
2.2. C4 nephritic factor 
Antibodies recognizing the classical pathway C3 convertase C4bC2b have been described and 
termed C4Nefs. C4Nefs are IgG autoantibodies that were first reported in a patient with 
postinfectious glomerulonephritis [42] and in patients with SLE [43]. Binding of C4Nef to the 
C4bC2b convertase prolongs the half-life of the convertase, preventing both the intrinsic and 
the C4b-binding protein-, CR1- or DAF-mediated extrinsic decay [19,44,45]. Stabilization of 
the C4bC2b convertase by C4Nef leads to enhanced C3 and C5 cleavage. C4Nef also protects 
the C4b fragment against cleavage by factor I [44]. C4Nef isolated from a patient with 
chronic glomerulonephritis was shown to bind to a neoepitope of the C4bC2b convertase [46], 
similar to the C4Nef analyzed by Gigli et al., that only inhibited C4b cleavage when it was in 
complex with C2b [44]. Presence of C4Nef was detected both alone and together with C3Nef 
in patients with glomerulonephritis [38,39]. Although the only study analyzing a cohort of 
100 hypocomplementemic MPGN patients reported a frequency of ~20% for C4Nef alone or 
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together with C3Nef [39], screening for C4Nef is currently not part of the routine diagnostics. 
C4Nef can be measured by hemolytic assay or ELISA [39,47]. Problems with the specificity 
and reliability of the assay are similar to the C3Nef assay, as discussed above. It is unclear at 
present if C4Nefs are common and if they are relevant to disease. Therefore, it would be 
worthwhile to clarify the frequency and relevance of C4Nef. 
 
2.3. Factor B and C3b autoantibodies 
Autoantibodies targeting the individual components of the C3bBb convertase, C3b and factor 
B, in glomerulonephritis patients were also described. At present, one patient with factor B 
autoantibody and two patients with combined factor B and C3b autoantibodies have been 
described in detail [11,48]. The factor B autoantibody, identified by ELISA in a DDD patient 
who was negative for C3Nef (as measured by the traditional hemolytic assay), bound both to 
native factor B in serum and to Bb in the solid-phase C3bBb convertase [11]. Thorough 
functional characterization of the factor B autoantibody revealed stabilization of the C3bBb 
convertase against both intrinsic and factor H-mediated decay, resulting in enhanced C3 
cleavage and activation of the alternative pathway. However, in contrast to most C3Nefs, this 
factor B antibody inhibited formation of the C5 convertase and terminal pathway activation 
[11]. The other two factor B autoantibodies described also recognized the whole factor B and 
the purified IgG increased Ba production [48]. The C3b antibodies were not further 
characterized. 
As in the case of C3Nefs and C4Nefs, there is no proof that these factor B 
autontibodies are cause of the disease; rather, they may appear secondarily due to the 
increased amounts of complement cleavage products in the plasma. Such a notion is 
supported by further analysis of the anti-factor B positive patient’s sample [11], indicating 
appearance of antibodies against several components of the C3bBb convertase, such as factor 
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B, C3b and properdin, although the factor B autoantibody is dominant (Fig. 2). In addition to 
these cases, Zhang et al. described factor B autoantibodies presenting together with C3Nef in 
three patients, but the antibodies were not characterized [37]. 
 
2.4. Factor H autoantibodies 
The first factor H autoantibody described was a „mini-autoantibody” consisting of lambda 
light chain dimers, detected in a patient with membranoproliferative glomerulonephritis [49]. 
This mini-autoantibody caused uncontrolled complement activation and C3 consumption 
when added to normal human serum via inhibiting factor H. Later, the binding site of this 
antibody was shown to be in domain 3 of factor H, i.e., in the N-terminal part of the molecule 
responsible for complement regulatory function (short consensus repeat [SCR] domains 1-4) 
[50]. 
Only very recently a few additional patients with factor H autoantibodies have been 
reported. One patient diagnosed with DDD had monoclonal gammopathy and autoantibodies 
against factor H and plasminogen [51]. The binding site of this autoantibody was in the N-
terminal complement regulatory domains of factor H and the isolated IgG fraction of the 
patient inhibited fluid-phase cofactor activity of factor H [51]. Interestingly, the antibody also 
bound to factor H-like protein 1 (CFHL1) [51], which is a splice variant derived from the 
CFH gene, and consists of the 7 N-terminal domains of factor H and a unique four aminoacid 
long tail. CFHL1 thus shares complement regulatory function with factor H. Analysis of the 
IgG fraction isolated from the patient showed that most autoantibody molecules were in fact 
bound to CFHL1 (Fig. 3). Although not tested, these autoantibodies are expected to inhibit the 
cofactor activity of CFHL1 as well. The relative contribution of factor H and CFHL1 to local 
or systemic complement inhibition is unclear, but this case suggests that CFHL1 deserves 
more attention as it could influence renal pathology. 
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Goodship et al. screened 16 patients with MPGN, of whom two patients were strongly 
positive for factor H autoantibodies [52]. One patient had MPGN type I without C3Nef, while 
the second patient had DDD and was positive for C3Nef. Both factor H autoantibodies bound 
predominantly to the N-terminal domains of factor H (SCRs 1-5) and in the second patient 
also to SCRs 8-15. IgG isolated from both patients increased alternative pathway mediated 
hemolysis of rabbit erythrocytes [52]. Both patients had two copies of CFHR1 and CFHR3. 
One patient diagnosed with glomerulonephritis with isolated C3 deposits and a low 
titer of factor H antibodies has also been reported, but the antibody was not characterized in 
detail [53]. In a recent study, a cohort of 32 patients with DDD was analyzed and one patient 
was found positive for factor H autoantibodies [37]. Binding sites of the autoantibodies have 
not been determined and functional analyses have not been performed. 
In summary, patients with glomerulonephritis should be screened for the presence of 
circulating factor H autoantibodies. The frequency of such antibodies – based on the current 
available literature – is markedly lower than that seen in aHUS (see below); however, 
systematic testing of patients should be performed to establish the frequency of these 
antibodies. To date, all four analyzed antibodies impaired the complement inhibitory function 
of factor H by binding to the complement regulatory domains (SCRs 1-5). Notably, two out of 
the four well-characterized factor H autoantibodies were monoclonal [49,51]. In a recent 
study, 10 of 32 patients with C3 glomerulonephritis had evidence of monoclonal gammopathy 
associated with complement activation and the authors suggested that monoclonal 
immunoglobulins acted as autoantibodies to complement-regulatory proteins [54]. This 
potential association should be investigated in the future. 
 
3. Autoantibodies in aHUS 
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The complement system is clearly involved in the disease pathomechanism in the majority of 
aHUS patients. Disease-associated polymorphisms, risk haplotypes and mutations in factor H, 
factor I, MCP, C3, factor B, thrombomodulin, and clusterin have been described [55]. 
Genomic rearrangements in the factor H gene cluster that affect the factor H gene (CFH) 
and/or some of the adjacent genes coding for factor H-related proteins (CFHR) are also 
known [55,56]. In addition to the genetic predisposing factors, acquired, autoimmune forms 
of aHUS are relatively frequent. Approximately 6-11% of aHUS patients have circulating 
anti-factor H antibodies [57] and 3 cases of factor I autoantibodies were reported recently 
[58]. 
 
3.1. Factor H autoantibodies 
Factor H autoantibodies were first reported in three children with aHUS [57] and have been 
described since then in many other aHUS patients. The autoantibodies are detected by ELISA 
that uses purified factor H and allows determination of antibody titers and follow-up of titer 
changes in response to treatment. Our own experiments as well as a recently published 
comparison of various test methods support the originally described factor H autoantibody 
ELISA as a robust and well reproducible assay [59-61]. Some patients have IgA class 
autoantibodies in addition to IgG [62]. Because the standard anti-factor H ELISA only 
measures free antibodies, a few studies investigated the factor H-IgG complexes in patient 
samples [62-65]. The results showed that in some patients with seemingly low antibody titer 
the majority of autoantibodies are in complex with factor H. The amount of complexes 
actually shows better correlation with the disease course than that of the free autoantibodies 
[64]. It is important to note that the autoantibodies may interfere with the measurement of 
factor H serum levels, depending on the antibodies used in the factor H ELISA, due to 
overlapping binding sites [61-63,66]. 
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Clinical features of factor H-autoantibody associated aHUS have been described [64]. 
Most patients are children, but a few adults are also reported. Interestingly, a recent report 
described Indian aHUS patients [67] among which the frequency of the autoantibodies is 
much higher (56%) than the previously reported 6-11% in three aHUS cohorts [57,68,69] and 
25% in a pediatric aHUS cohort [70], indicating that population differences in genetic and/or 
environmental predisposing factors play important roles. 
The overwhelming majority of factor H autoantibody positive aHUS patients present 
with the homozygous deletion of the CFHR1 gene, which in most cases is deleted together 
with CFHR3 due to non-allelic homologous recombination [67-72]. In a few patients other 
genomic alterations are identified, such as CFHR1 deletion together with CFHR4 deletion, or 
combined CFHR3-CFHR1 and CFHR1-CFHR4 deletions [69,72]. Factor H autoantibodies 
can also be associated with mutations in CFHR1, factor H, C3, MCP or factor I [69,72]. The 
strong association between the lack of CFHR1 and the presence of the factor H autoantibodies 
suggests that CFHR1 is required to induce and/or maintain tolerance against factor H. 
Because the CFHR3-CFHR1 deletion is common in the healthy population, other 
predisposing genes (such as certain HLA haplotypes) and environmental factors (such as 
infections) are suspected. The role of infection in the generation of autoantibodies is 
supported by the generally young age of the patients and because an infection is often 
observed prior to disease manifestation [64,67,68]. 
The binding sites of the factor H autoantibodies were mapped in a few studies. The 
first investigations demonstrated that the major autoantibody binding site lies in the C-
terminal domains of factor H (particularly SCR20), which are responsible for the binding of 
factor H to cell surfaces, thus protecting autologous cells from complement-mediated damage 
[68,73]. This was confirmed recently by other studies [65,69]. However, the autoantibodies 
may bind to other parts of the factor H molecule, such as SCRs 8-11 [68,69] or even to the 
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complement regulatory domains SCRs 1-4 [65,69], as detected in samples collected in the 
acute phase of the disease [65]. Thus, autoantibodies may bind to various domains and inhibit 
several functions of factor H. 
Most of the described factor H autoantibodies also recognize CFHR1, due to strong 
sequence similarity of its C-terminal domains with the homologous domains of factor H. 
[62,65,69]. This fact could be most relevant for understanding why the vast majority of aHUS 
patients with factor H autoantibodies is CFHR1-deficient. A recent report also showed cross-
reactivity with the factor H-related protein CFHR2 [65]. 
Functional analyses of aHUS-associated autoantibodies demonstrated impaired 
binding to surface-deposited C3b and host-like surfaces, leading to reduced protection from 
complement-mediated lysis that is routinely measured by a hemolytic assay using sheep 
erythrocytes [62,63,73]. Autoantibodies may interfere with the cofactor- and convertase decay 
accelerating activity of factor H [57,65]. In addition, factor H autoantibodies may impair the 
interaction of both factor H and CFHR1 with pentraxin 3 [74]. These data further demonstrate 
that multiple functions of factor H could be inhibited by the autoantibodies, but there are 
differences in this regard among the patients. 
Altogether, aHUS-associated factor H autoantibodies differ from those found in 
patients with DDD/C3 glomerulopathy. The binding sites (N-terminal in DDD/MPGN and 
predominantly C-terminal in aHUS) and effects on factor H functions are different. Moreover, 
factor H autoantibodies are strongly associated with CFHR1 deletion in aHUS whereas 
similar genetic predisposition to the development of factor H autoantibodies in C3 
glomerulopathy is currently not supported by evidence. 
 
3.2. Factor I autoantibodies 
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In three out of 175 investigated aHUS patients autoantibodies to factor I were detected by 
ELISA [58]. Both free antibodies and circulating complexes were measured. Functional 
analysis of available samples demonstrated no significant effect on factor I function, and it is 
possible that such antibodies are epiphenomena. During our own studies, we have detected 
factor I antibodies of IgG3 class in two aHUS serum samples. Such antibodies were not 
detected in controls and the binding to factor I was specific (Fig. 4). The frequency of these 
autoantibodies in aHUS (< 2%) is clearly less than that of the factor H autoantibodies (6-
11%). The potential pathogenic role and diagnostic utility of the factor I autoantibodies 
remains unknown. 
 
3.3. C3b autoantibodies 
When screening patient samples for autoantibodies by ELISA, we use several antigens as 
controls and to identify possible novel antibodies. In one aHUS patient, specific IgG binding 
to C3b was found, without the presence of factor H autoantibodies. When further analyzing 
this sample, it became apparent that the antibody bound to the C3b and iC3b fragments, but 
poorly to intact C3 and not to C3d (Fig. 5). It is possible that such antibody is generated due 
to the sustained complement activation during disease and it may contribute to pathologic 
complement activation; however, a direct pathogenic role is uncertain. 
 
4. Treatment options 
In the above mentioned autoimmune kidney diseases pathogenic autoantibodies against 
complement proteins are therapeutic targets. The aim of the therapy can be neutralization of 
the pathogenic autoantibodies, replacement of the affected complement components in the 
acute phase of the disease, as well as the reduction of the titer of autoantibodies with the 
elimination of antibody producing B cells. Plasma exchanges are often applied in combination 
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with immune adsorption and/or immunosuppressive therapy (such as corticosteroids, pulse 
cyclophosphamide treatment or targeted B cell depletion with rituximab). Available clinical 
data suggest a good efficacy of plasma exchanges and immunosuppression in factor H 
autoantibody-associated aHUS [63,64,67,75-77]. Similarly, factor H-associated DDD was 
successfully treated [51]. Importantly, the autoantibodies should also be eliminated before 
kidney transplantation [48,78,79]. 
The efficacy of eculizumab, a humanized monoclonal antibody directed against C5, 
was recently demonstrated in patients with complement-mediated aHUS [80] and according to 
case reports also in some patients with various forms of C3 glomerulopathy [8,81-84]. This 
drug was successfully used in patients with autoantibody mediated forms of the above 
diseases [85] pointing towards the importance of terminal pathway activation and generation 
of inflammation in these diseases [86]. It is important to note that eculizumab inhibits further 
activation at C5, but the underlying complement activation and C3 consumption is not 
inhibited by the drug. Thus, other complement inhibitors targeting uncontrolled C3 activation 
may be useful in the treatment of such diseases. 
Purified complement proteins may be considered to increase the level of functionally 
active, antibody-free factors, such as purified or recombinant factor H, to restore 
physiological complement regulation. In addition to the production of recombinant full-length 
factor H [87], two recent reports described an engineered „mini-FH” in which domains 5-18 
are deleted, thus the protein is reduced to the complement regulatory (SCRs 1-4) and surface 
recognition (SCRs 19-20) domains. Such recombinant constructs were even more effective 
than full-length factor H in inhibiting complement C3 deposition in vitro on paroxysmal 
nocturnal hemoglobinuria-erythrocytes [88] and on endothelial cells, as well as inhibiting 
factor H autoantibody-induced hemolysis of host-like cells [89]. After further development 
and optimization, such targeted inhibitors might effectively prevent uncontrolled complement 
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activation in the acute phase of disease and help reduce or even prevent complement-mediated 
damage to the kidney. 
 
5. Conclusion 
The discussed complement-specific autoantibodies are summarized in Table I. 
In C3 glomerulopathy, in addition to the commonly detected C3Nef, rarely other 
antibodies are identified. The example shown in Fig. 3 demonstrates weak antibody positivity 
to C3b and properdin, in addition to factor B, indicating the presence of autoantibodies to all 
components of the convertase. Systematic screening of patients and detailed characterization 
of the individual antibodies are needed to understand their frequency and relevance in the 
disease. 
In aHUS, the importance of factor H autoantibodies is established, whereas other 
autoantibodies, such as those against factor I [58] and C3b can occassionally be detected in 
patients with aHUS, as also shown here (Figs. 4 and 5). The rare cases of factor I and C3b 
autoantibodies with unknown significance, as well as false positive results for factor H 
autoantibodies [59,61] suggest that caution should be taken in the interpretation of ELISA 
results and, particularly, before commencing perhaps unnecessary immunosuppressive 
treatment. 
 In summary, factor H autoantibodies are targeted against different epitopes in C3 
glomerulopathy/DDD and aHUS. Autoantibodies to factor I and C3b are rare and their 
functional relevance is yet unclear. Autoantibodies to the C3 convertase or its components are 
common in C3 glomerulopathy, but may be secondary phenomena due to the increased 
amounts of complement activation products in the patients. Because of the convertase 
stabilization effect of these autoantibodies, it is important to be aware of their presence. 
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It is vital to identify the autoantibodies as soon as possible because timely and targeted 
therapy increases the chance of successful treatment. The pathogenic factor H autoantibodies 
can be quickly (within 24-48 hours) and easily detected by ELISA and the antibody titers can 
be monitored during disease course by this inexpensive and robust method. It is recommended 
to screen aHUS and C3 glomerulopathy patients for factor H autoantibodies in a timely 
manner, regardless of the suspicion for possible genetic risk factors in the patients. The 
relevance of positivity for anti-factor I, anti-C3b or anti-properdin antibodies is unclear at the 
moment because of the limited data, the relatively low titers in the reported cases and 
uncertainty of functional effects and pathogenicity of the antibodies. Whereas the direct 
pathogenic role of C3Nef is not clear and C3Nef is more difficult to detect due to the 
antigenic and functional heterogeneity of these autoantibodies, it is recommended to apply a 
combination of tests for the identification of C3Nef, which if positive, corroborates the 
disease diagnosis and may be helpful in choosing therapy (such as complement inhibition) 
and monitoring response to treatment. Similarly, detection of factor B autoantibodies is easily 
done by ELISA and a positive result confirms the role of alternative complement pathway. 
With eculizumab available and novel complement inhibitors in the development 
pipeline, new, emerging options for treatment could be considered and tried in the future, 
possibly allowing tailored therapy. The successful treatment may include inhibition of 
complement activation and replacement of dysfunctional proteins, removal of immune 
complexes and attempts to eliminate autoantibody producing cells. 
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aHUS, atypical hemolytic uremic syndrome; BSA, bovine serum albumin; C3Nef, C3 
nephritic factor; C4Nef, C4 nephritic factor; CFHR, complement factor H-related; DDD, 
dense deposit disease; MPGN, membranoproliferative glomerulonephritis; NHP, normal 
human plasma; SCR, short consensus repeat 
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Figure legends 
Fig. 1. Schematic view of complement activation. The complement system can be activated 
through three major pathways. The classical and lectin pathways lead to the generation of the 
C3 convertase enzyme C4bC2b that cleaves C3 into C3a and C3b. Similarly, alternative 
pathway activation leads to the generation of the C3 convertase enzyme C3bBb that cleaves 
C3. In addition, C3b generated by any pathway feeds into the alternative pathway by forming 
C3bBb enzymes. When C3b deposits to either C4bC2b or C3bBb, the enzymes gain the 
ability to cleave C5 into C5a and C5b, the latter initiating the terminal complement pathway 
that may eventually lead to the formation of terminal complement complexes and allow lysis 
of target cells. The activation of complement is regulated by several soluble and membrane-
bound molecules. The figure shows those regulators to which autoantibodies in C3 
glomerulopathy and aHUS have been described. The antibodies target the C3 convertase or its 
components (C3b and factor B), its negative regulators (factor H and factor I), or the positive 
regulator properdin. 
Fig. 2. Specificity of a DDD-associated factor B autoantibody. An ELISA was used to 
analyze the binding of IgGs from sera (diluted 1:100) of a DDD patient with factor B 
autoantibodies (black bars), an aHUS patient with factor H autoantibodies (dotted bars), or a 
healthy control (white bars), to the C3 convertase components factor B (FB) and C3b, and to 
the regulators properdin (FP) and factor H (FH), which were immobilized at 5 µg/ml. Bovine 
serum albumin (BSA) was used as control of unspecific binding. Data are mean + SD of three 
experiments. 
Fig. 3. Western blot analysis of a dense deposit disease-associated factor H autoantibody. 
(A) Serum IgG fractions were isolated from an anti-factor H positive patient with DDD (lane 
1), a patient with aHUS and factor H autoantibodies (lane 2), and a healthy donor (lane 3). 10 
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µg of the IgG fractions was separated on 10% SDS-PAGE and transferred to nitrocellulose 
membrane. In lane 4, 1 µl normal human plasma (NHP) was run as a control. The membrane 
was developed using a monoclonal antibody recognizing domain 1 of factor H and factor H-
like protein 1 (CFHL1). The IgG fractions of the patients (lanes 1 and 2) contained both free 
autoantibodies and immune complexes. (B) The schematic drawing shows the 20 factor H 
domains and the domains of CFHL1, which is generated from the CFH gene by alternative 
splicing. CFHL1 contains the 7 N-terminal domains of factor H, including the four domains 
responsible for complement regulation (shown in grey), and four C-terminal amino acids, not 
present in factor H. Thus, CFHL1 and factor H share complement regulatory activity. 
Fig. 4. Characterization of aHUS-associated factor I autoantibodies by ELISA. (A) 
Serum immunoglobulins from two aHUS patients bind to immobilized factor I (5 µg/ml) in a 
dose-dependent manner. Three control sera are shown for comparison. Data of a 
representative experiement are shown. (B) Binding to immobilized factor I before and after 
IgG-depletion by incubation with protein G (sera diluted 1:100). Data are mean + SD of three 
experiments. (C) Dose-dependent binding of purified IgG from patient 1 to immobilized 
factor I; no binding is observed with a control IgG. Data are mean + SD of three experiments. 
(D) The binding of autoantibodies from the serum of patient 1 (diluted 1:100) to immobilized 
factor I was inhibited by adding purified factor I, whereas BSA had no inhibitory effect. Data 
of a representative experiement are shown. 
Fig. 5. Characterization of C3b autoantibodies from an aHUS patient by ELISA. (A) IgG 
binding to C3, C3b, iC3b, C3d and BSA (immobilized at 5 µg/ml) observed with the patient’s 
serum and with a control serum (both diluted 1:100). (B) The patient’s autoantibodies bind to 
immobilized C3b in a dose-dependent manner. IgG binding from a control serum is shown for 
comparison. (C) IgG binding to immobilized C3b before and after IgG-depletion (sera diluted 
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1:100). (D) Autoantibody binding to C3b can be inhibited by adding purified C3b to the 
patient’s plasma (diluted 1:100), whereas factor H had no inhibitory effect. Data represent 
mean + SD of three experiments. 
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